🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 10 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 26/05/2020 | 287,95 | 288,50 | 264,41 | 266,50 | -6,48% | 8,37% | 3.487.000 |
| 22/05/2020 | 284,18 | 286,00 | 281,52 | 284,96 | +0,12% | 1,58% | 1.066.500 |
| 21/05/2020 | 285,26 | 285,40 | 281,25 | 284,63 | +0,00% | 1,45% | 1.315.000 |
| 20/05/2020 | 284,81 | 285,99 | 282,13 | 284,62 | +0,83% | 1,36% | 1.436.500 |
| 19/05/2020 | 285,30 | 288,41 | 281,14 | 282,28 | -0,65% | 2,55% | 1.267.200 |
| 18/05/2020 | 293,78 | 295,55 | 283,10 | 284,13 | -1,58% | 4,24% | 1.727.000 |
| 15/05/2020 | 275,63 | 288,73 | 273,51 | 288,69 | +4,22% | 5,52% | 1.740.100 |
| 14/05/2020 | 277,56 | 282,48 | 272,21 | 277,00 | -0,01% | 3,70% | 3.076.100 |
| 13/05/2020 | 276,60 | 284,86 | 272,19 | 277,03 | +0,20% | 4,58% | 1.644.900 |
| 12/05/2020 | 287,33 | 288,52 | 276,41 | 276,47 | -3,09% | 4,21% | 1.727.500 |
| 11/05/2020 | 271,45 | 286,82 | 270,44 | 285,28 | +5,03% | 6,03% | 2.068.500 |
| 08/05/2020 | 269,50 | 274,41 | 268,29 | 271,63 | +0,60% | 2,27% | 1.084.100 |
| 07/05/2020 | 272,69 | 273,72 | 266,83 | 270,01 | -0,02% | 2,53% | 1.622.000 |
| 06/05/2020 | 272,33 | 275,55 | 268,00 | 270,06 | -0,83% | 2,77% | 1.290.200 |
| 05/05/2020 | 266,97 | 274,06 | 264,80 | 272,33 | +2,89% | 3,47% | 1.934.300 |
| 04/05/2020 | 257,40 | 265,00 | 256,01 | 264,69 | +3,84% | 3,49% | 2.650.300 |
| 01/05/2020 | 249,26 | 256,00 | 248,00 | 254,90 | +1,47% | 3,21% | 1.940.200 |
| 30/04/2020 | 257,75 | 258,50 | 245,06 | 251,20 | +0,06% | 5,21% | 2.825.200 |
| 29/04/2020 | 260,97 | 262,00 | 250,52 | 251,05 | -2,30% | 4,40% | 2.401.700 |
| 28/04/2020 | 268,00 | 269,95 | 250,43 | 256,96 | -4,30% | 7,28% | 2.338.300 |
| 27/04/2020 | 275,00 | 275,26 | 267,16 | 268,51 | -0,50% | 2,95% | 2.181.600 |
| 24/04/2020 | 270,12 | 271,35 | 266,43 | 269,86 | +0,73% | 1,82% | 1.805.800 |
| 23/04/2020 | 270,03 | 277,80 | 266,92 | 267,91 | -0,54% | 4,03% | 2.770.400 |
| 22/04/2020 | 267,15 | 271,25 | 264,00 | 269,37 | +2,50% | 2,71% | 1.546.000 |
| 21/04/2020 | 273,00 | 277,22 | 262,55 | 262,80 | -3,83% | 5,37% | 1.602.700 |
| 20/04/2020 | 271,97 | 276,26 | 269,05 | 273,26 | +1,04% | 2,65% | 1.967.800 |
| 17/04/2020 | 272,34 | 272,67 | 265,15 | 270,46 | +2,15% | 2,76% | 2.166.700 |
| 16/04/2020 | 259,67 | 265,28 | 258,61 | 264,76 | +3,73% | 2,57% | 2.172.800 |
| 15/04/2020 | 260,90 | 262,82 | 254,31 | 255,23 | -2,74% | 3,26% | 2.686.500 |
| 14/04/2020 | 257,44 | 265,66 | 253,51 | 262,41 | +4,02% | 4,72% | 2.180.500 |